Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Jan, van Lunzen"'
Autor:
Louise E. van Eekeren, Quirijn de Mast, Elise M.G. Meeder, Adriana Navas, Albert L. Groenendijk, Marc J.T. Blaauw, Wilhelm A.J.W. Vos, Nadira Vadaq, Jéssica C. Dos Santos, Joost Rutten, Niels P. Riksen, Jan van Lunzen, Gert Weijers, Mihai G. Netea, André J.A.M. van der Ven, Eric T.T.L. Tjwa, Leo A.B. Joosten
Publikováno v:
EBioMedicine, Vol 109, Iss , Pp 105407- (2024)
Summary: Background: Insights into the mechanisms driving metabolic dysfunction-associated steatotic liver disease (MASLD) in people living with HIV (PLHIV) remain limited. Plasma proteomics holds promise for biomarker discovery and the elucidation o
Externí odkaz:
https://doaj.org/article/ef271a81f9d744ecb5a25b46cb60e8f7
Autor:
Wilhelm A. J. W. Vos, Adriana Navas, Elise M. G. Meeder, Marc J. T. Blaauw, Albert L. Groenendijk, Louise E. van Eekeren, Twan Otten, Nadira Vadaq, Vasiliki Matzaraki, Bram van Cranenbroek, Kees Brinkman, Jan van Lunzen, Leo A. B. Joosten, Mihai G. Netea, Willem L. Blok, Andre J. A. M. van der Ven, Hans J. P. M. Koenen, Janneke E. Stalenhoef
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionImmunological non-responders (INR) are people living with HIV (PLHIV) who fail to fully restore CD4+ T-cell counts despite complete viral suppression with antiretroviral therapy (ART). INR are at higher risk for non-HIV related morbidity
Externí odkaz:
https://doaj.org/article/fe9f62a30ced4509bab65036784e5714
Autor:
Wilhelm A. J. W. Vos, Nadira Vadaq, Vasiliki Matzaraki, Twan Otten, Albert L. Groenendijk, Marc J. T. Blaauw, Louise E. van Eekeren, Kees Brinkman, Quirijn de Mast, Niels P. Riksen, Anton F. H. Stalenhoef, Jan van Lunzen, Andre J. A. M. van der Ven, Willem L. Blok, Janneke E. Stalenhoef
Publikováno v:
Viruses, Vol 16, Iss 4, p 582 (2024)
In people living with HIV (PLHIV), integrase strand transfer inhibitors (INSTIs) are part of the first-line combination antiretroviral therapy (cART), while non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are alternatives. Disti
Externí odkaz:
https://doaj.org/article/f709bcd454a146f98691dffd7cf32341
Autor:
Wilhelm A. J. W. Vos, Albert L. Groenendijk, Marc J. T. Blaauw, Louise E. van Eekeren, Adriana Navas, Maartje C. P. Cleophas, Nadira Vadaq, Vasiliki Matzaraki, Jéssica C. dos Santos, Elise M. G. Meeder, Janeri Fröberg, Gert Weijers, Yue Zhang, Jingyuan Fu, Rob ter Horst, Christoph Bock, Rainer Knoll, Anna C. Aschenbrenner, Joachim Schultze, Linos Vanderkerckhove, Talent Hwandih, Elizabeth R. Wonderlich, Sai V. Vemula, Mike van der Kolk, Sterre C. P. de Vet, Willem L. Blok, Kees Brinkman, Casper Rokx, Arnt F. A. Schellekens, Quirijn de Mast, Leo A. B. Joosten, Marvin A. H. Berrevoets, Janneke E. Stalenhoef, Annelies Verbon, Jan van Lunzen, Mihai G. Netea, Andre J. A. M. van der Ven
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundEven during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comor
Externí odkaz:
https://doaj.org/article/f14192315814451f88d8bd0a0e732f4f
Autor:
Guido Schäfer, Christian Hoffmann, Keikawus Arasteh, Dirk Schürmann, Christoph Stephan, Björn Jensen, Matthias Stoll, Johannes R. Bogner, Gerd Faetkenheuer, Jürgen Rockstroh, Hartwig Klinker, Georg Härter, Albrecht Stöhr, Olaf Degen, Eric Freiwald, Anja Hüfner, Sabine Jordan, Julian Schulze zur Wiesch, Marylyn Addo, Ansgar W. Lohse, Jan van Lunzen, Stefan Schmiedel, the IDEAL study group
Publikováno v:
AIDS Research and Therapy, Vol 16, Iss 1, Pp 1-8 (2019)
Abstract Background To evaluate clinical outcomes after either immediate or deferred initiation of antiretroviral therapy in HIV-1-infected patients, presenting late with pneumocystis pneumonia (PCP) or toxoplasma encephalitis (TE). Methods Phase IV,
Externí odkaz:
https://doaj.org/article/82290680ddf94e3c96d93f441f9081ba
Autor:
Lisa Van de Wijer, Wouter A. van der Heijden, Rob ter Horst, Martin Jaeger, Wim Trypsteen, Sofie Rutsaert, Bram van Cranenbroek, Esther van Rijssen, Irma Joosten, Leo Joosten, Linos Vandekerckhove, Till Schoofs, Jan van Lunzen, Mihai G. Netea, Hans J.P.M. Koenen, André J.A.M. van der Ven, Quirijn de Mast
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Long-term changes in the immune system of successfully treated people living with HIV (PLHIV) remain incompletely understood. In this study, we assessed 108 white blood cell (WBC) populations in a cohort of 211 PLHIV on stable antiretroviral therapy
Externí odkaz:
https://doaj.org/article/e9c41e13fb5e4b64bc9b68de40eb9eb4
Autor:
Wouter A. van der Heijden, Lisa Van de Wijer, Farid Keramati, Wim Trypsteen, Sofie Rutsaert, Rob ter Horst, Martin Jaeger, Hans J.P.M. Koenen, Hendrik G. Stunnenberg, Irma Joosten, Paul E. Verweij, Jan van Lunzen, Charles A. Dinarello, Leo A.B. Joosten, Linos Vandekerckhove, Mihai G. Netea, André J.A.M. van der Ven, Quirijn de Mast
Publikováno v:
JCI Insight, Vol 6, Iss 7 (2021)
Chronic inflammation and immune dysfunction play a key role in the development of non-AIDS–related comorbidities. The aim of our study was to characterize the functional phenotype of immune cells in people living with HIV (PLHIV). We enrolled a cro
Externí odkaz:
https://doaj.org/article/b2994f3dd9f54fcfa5fbfca638fec075
Autor:
Jürgen K Rockstroh, David Asmuth, Giuseppe Pantaleo, Bonaventura Clotet, Daniel Podzamczer, Jan van Lunzen, Keikawus Arastéh, Ronald Mitsuyasu, Barry Peters, Nozza Silvia, Darren Jolliffe, Mats Ökvist, Kim Krogsgaard, Maja A Sommerfelt
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210965 (2019)
BACKGROUND:Vacc-4x, a therapeutic HIV vaccine candidate has previously induced a significant reduction in viral load (VL) set-point compared to placebo upon interruption of combination anti-retroviral therapy (ART) (2007/1 study). This study, (2012/1
Externí odkaz:
https://doaj.org/article/0bf3f95c684d4befbb874ae8332339ff
Autor:
Monique Nijhuis, Steven G. Deeks, Richard Dunham, Marein A. W. P. de Jong, Marein de Jong, Thanyawee Puthanakit, Mirko Paiardini, Santiago Perez Patrigeon, Krista L. Dong, Jan van Lunzen, Luke Jasenosky, Jessica Salzwedel, Simon Collins, Katharine J. Bar, Frank Mardarelli, Jeffrey T. Safrit, Jeremy Sugarman, Alex Schneider, Nancie M. Archin, Zaza M. Ndhlovu, Joel N. Blankson, Zabrina L. Brumme, Hans-Peter Kiem, Gaerolwe Masheto, Beatriz Mothe, Karine Dubé, Katherine Luzuriaga, Jennifer Power, Sarah Fidler, Richard Jefferys, Fu Sheng Wang, Jeff Taylor, Kumitaa Theva Das, Boro Dropulic, Kai Deng, Devi SenGupta, Sharon Lewin, Marina Caskey, Susana T. Valente, Siegfried Schwarze, Nicolas Chomont, R. Brad Jones, Ole S. Søgaard, Paula M. Cannon, Olivier Lambotte, Edward Nelson Kankaka, Gabriela Turk, Christina Antoniadi, Udom Likhitwonnawut, Caroline T. Tiemessen, Pablo Tebas, Rosanne Lamplough, Cissy Kityo, Fernanda Heloise Côrtes, Melannie Ott, Rose Nabatanzi, Oguzhan Latif Nuh, Mitch Matoga, Linos Vandekerckhove, J. Victor Garcia, Thumbi Ndung'u, Bonnie J. Howell, Aurelio Orta-Resendiz, Ricardo Sobhie Diaz, Michael Louella, Ann Chahroudi, Deborah Persaud, Stephan Dressler, Josephine Nabukenya, Sharon R Lewin
Publikováno v:
Nature Medicine. 27:2085-2098
Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These latently infected cell
Autor:
Veerle Van Eygen, David A. Margolis, Marty St. Clair, Jerry Jeffrey, Daniel R. Kuritzkes, Michael Aboud, Jan van Lunzen, Yongwei Wang, William Spreen, Christine L. Talarico, Mark Baker, Kati Vandermeulen, Amy Cutrell, Carlo Federico Perno, Jonathan M. Schapiro, David Dorey, Susan L. Ford, Herta Crauwels, C. Thomas White, Joseph W. Polli, Romina Quercia, Simon Vanveggel, Sterling Wu, Parul Patel
Publikováno v:
AIDS (London, England)
Current antiretroviral therapy (ART) consists of a combination of two or more oral agents from at least two drug classes, such as an integrase strand transfer inhibitor (INSTI) as well as one or two nucleoside reverse transcriptase inhibitors (NRTIs)